Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Posts 7 Percent Q1 Revenue Growth

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PerkinElmer reported after the close of the market Thursday that its first-quarter revenues increased 7 percent, with a 4 percent benefit from acquisitions and a 1 percent contribution from acquisitions.

The Waltham, Mass.-based firm reported total revenues of $465.1 million for the three-month period ended April 4, compared to $435.2 million for the first quarter of 2009. Sales for its Human Health segment increased 6 percent to $188.6 million from $177.3 million, while sales for its Environmental Health segment increased 19 percent to $276.5 million from $257.9 million.

The firm surpassed analysts' consensus expectations for revenues of $446.8 million.

PerkinElmer posted a profit of $24.4 million, or $.21 per share, compared to $10.6 million, or $.09 per share, for the first quarter of 2009. Its adjusted EPS was $.31, beating analysts' consensus estimate of $.29.

The firm's R&D spending rose 3 percent to $27.1 million from $26.2 million, while its SG&A spending increased around 2 percent to $132.1 million from $129.1 million.

PerkinElmer finished the quarter with $181.7 million in cash and cash equivalents.

The firm expects its full-year 2010 GAAP EPS to be between $1.08 and $1.13, and non-GAAP EPS of between $1.43 and $1.48.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.